Divalproex Sodium Tablet, Delayed Release
Product Images NDC 62756-798

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 62756-798). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

Bar graph titled Figure 1 showing percentage comparisons between placebo (PBO) and Divalproex Sodium (DVPX) groups across two studies. Study 1 uses YMRS with 26% for PBO and 60% for DVPX. Study 2 uses MRS with 29% for PBO and 58% for DVPX. The y-axis represents percentage values from 0% to 70%.*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

A cumulative percentage graph comparing the percentage reduction in CPS rate between patients treated with Divalproex Sodium (DVPX) and placebo. The x-axis represents the percentage of patients from 100% to 0%, and the y-axis shows the percentage reduction in CPS rate from -100% to 100%, with arrows indicating improvement and worsening.*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

A chart labeled Figure 3 illustrating the percentage reduction in CPS rate versus the percentage of patients. It compares high dose and low dose treatments, showing improvement, no change, and worsening on a vertical axis.*

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

A bar graph titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates between Placebo and Divalproex Sodium (DVPX) in two studies. The vertical axis represents migraine rates from 0 to 6. Study 1 shows higher rates for Placebo than DVPX, and Study 2 shows similarly higher rates for Placebo compared to DVPX.*

FDA Label Image

Spl-divalproex-label-125mg (Spl Divalproex Label 125mg)

Label for Divalproex Sodium 125 mg delayed-release tablets, USP by Sun Pharmaceutical Industries, Inc. The label includes the strength (125 mg) highlighted in orange, mentions valproic acid activity, and specifies the package contains 30 tablets. It also has a barcode and the text instructing pharmacists to dispense a medication guide to each patient.*

FDA Label Image

Spl-divalproex-label-250mg (Spl Divalproex Label 250mg)

Label for Divalproex Sodium Delayed-Release Tablets, USP 250 mg by Sun Pharmaceutical Industries, Inc. The label indicates 30 tablets per bottle with valproic acid activity and oral route. It includes dosage instructions, storage conditions, and distribution information from Sun Pharma. Barcode and NDC 62756-797-83 are shown.*

FDA Label Image

Spl-divalproex-label-500mg (Spl Divalproex Label 500mg)

Label for Divalproex Sodium delayed-release tablets, USP 500 mg oral dosage form. The label notes valproic acid activity, includes a barcode, and specifies 30 tablets per container. Distributed and manufactured by Sun Pharmaceutical Industries, with details on storage and handling instructions visible on the label.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Chemical structure of divalproex sodium depicting the polymeric form with sodium ions and carboxylate groups, consistent with the active ingredient in the Divalproex Sodium delayed release tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.